How long should women avoid pregnancy after receiving the Measles, Mumps, and Rubella (MMR) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

MMR Vaccine and Pregnancy Avoidance

Women should be counseled to avoid pregnancy for 3 months after receiving the MMR vaccine or other rubella-containing vaccines. 1

Recommended Waiting Period After MMR Vaccination

  • Women should avoid pregnancy for 30 days after receiving monovalent measles or mumps vaccines 1
  • Women should avoid pregnancy for 3 months after receiving MMR or other rubella-containing vaccines 1
  • The most recent guidance (2011) recommends avoiding pregnancy for 28 days after receipt of rubella-containing vaccine 1

Rationale for Pregnancy Avoidance

  • The recommendation is based on theoretical concerns about potential risk to the fetus from live virus vaccines 1
  • Although the risk is theoretical, it cannot be completely excluded, which is why pregnancy avoidance is recommended 1
  • The rubella component of the vaccine is the primary concern driving the longer waiting period 1

Safety Data if Pregnancy Occurs

  • If a woman becomes pregnant within 3 months after MMR vaccination, she should be counseled about the theoretical basis of concern, but this is not ordinarily a reason to consider pregnancy termination 1
  • No cases of congenital rubella syndrome or abnormalities attributable to vaccine virus infection have been observed in infants born to susceptible mothers who received MMR during pregnancy 1
  • Long-term follow-up of 321 rubella-susceptible women who were vaccinated within 3 months before or after conception showed:
    • None of the 324 infants had malformations compatible with congenital rubella syndrome 1
    • Five infants had evidence of subclinical infection 1
    • The estimated risk for serious malformations attributable to RA 27/3 rubella vaccine ranges from zero to 1.6% 1

Clinical Practice Recommendations

  • Healthcare providers should:

    • Ask women if they are pregnant before administering MMR 1
    • Not vaccinate women who state they are pregnant 1
    • Explain the potential theoretical risk to women who state they are not pregnant 1
    • Counsel women who are vaccinated to avoid pregnancy for 3 months 1
  • For postpartum women:

    • Non-immune women should receive MMR vaccine before discharge from the hospital or birthing center 2
    • Breastfeeding is not a contraindication to MMR vaccination 1
    • Although rubella vaccine virus can be excreted in breast milk, the infection remains asymptomatic in the infant 1

Special Considerations

  • During pre-pregnancy counseling, MMR vaccination should be offered with advice to avoid pregnancy for the recommended period 3
  • For women planning pregnancy, ensuring MMR immunity before conception is preferable to postpartum vaccination 2
  • Women who are not vaccinated because they are pregnant should be counseled about the risk of congenital rubella syndrome and the importance of vaccination after pregnancy 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Rubella Vaccination for Non-Immune Postpartum Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Vaccines - safety in pregnancy.

Best practice & research. Clinical obstetrics & gynaecology, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.